CDK4/6 Inhibition in Early-Stage HR+, HER2- Breast Cancer

Via Peters

Kevin Kalinsky, MD, MS: We’ve known from metastatic disease that with CDK4/6 inhibitors there can be significant advantage of utilizing them in the metastatic setting. And we’ve seen across the various studies in the metastatic setting progression-free survival benefit and for some of the agents an overall survival benefit. So […]